Phil Hagerman receives prestigious Ernst & Young award
Phil Hagerman, RPh, president and CEO of Diplomat Specialty Pharmacy, was named Ernst & Young Entrepreneur of the Year for the Michigan and Northwest Ohio region. He was honored June 10 at an awards ceremony in Dearborn, Mich.
Phil Hagerman, RPh, president and CEO of Diplomat Specialty Pharmacy, was named Ernst & Young Entrepreneur of the Year for the Michigan and Northwest Ohio region. He was honored June 10 at an awards ceremony in Dearborn, Mich.
Recognized globally, the Ernst & Young Entrepreneur of the Year Award is the world’s most prestigious business accolade for outstanding entrepreneurs who inspire others with their vision, leadership, and achievement. As the Michigan/Northwest Ohio winner in the Retail and Services category, Hagerman is now a candidate for the National Entrepreneur of the Year award, which will be announced at the annual Ernst & Young awards event in November in Palm Springs, Calif.
Hagerman founded Diplomat Specialty Pharmacy in 1975 with his father, pharmacist Dale Hagerman. The company quickly entered the developing niche field of specialty pharmacy, a branch of the pharmaceutical delivery system that focuses on comprehensive and coordinated systems of pharmacological care for patients with serious and chronic illnesses and complex medical conditions.
Diplomat Specialty Pharmacy, based in Swartz Creek, Mich., offers its services through contracts with prescription benefit managers and health plans, and through direct relationships with physicians, patients, and pharmaceutical companies. The company also provides services to large retail pharmacies not equipped to handle the pharmaceutical needs of patients requiring expensive, highly specialized drugs.
The specialty pharmacy category - recently pegged as a $100 billion industry, with recent and anticipated annual growth of 15% to 20% per year - is growing as a result of new medications and therapies entering the marketplace.
According to Diplomat Specialty Pharmacy, members of the pharmacy community have begun to take a more active role in healthcare as part of a coordinated healthcare team. This is especially significant as an estimated 30 million new patients are expected to join the ranks of the insured as a result of healthcare reform.
How Differences in Bispecific Therapies Impact Myeloma Treatment Operations
April 18th 2024According to Kirollos Hanna, PharmD, although similarities exist between bispecific therapies in the myeloma space, health care providers should take special note of practical differences and nuances associated with each when operationalizing them at their site of care.
